Theratechnologies (THTX) News Today → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free THTX Stock Alerts $1.31 -0.02 (-1.50%) (As of 04:28 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | globenewswire.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 2, 2024 | globenewswire.comTheratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO MeetingApril 15, 2024 | globenewswire.comTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ShareholdersApril 11, 2024 | seekingalpha.comTheratechnologies Inc. (THTX) Q1 2024 Earnings Call TranscriptApril 11, 2024 | globenewswire.comTheratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | investorplace.comTHTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024April 10, 2024 | globenewswire.comTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024April 10, 2024 | globenewswire.comTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024April 8, 2024 | globenewswire.comTheratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology PlatformApril 5, 2024 | globenewswire.comTheratechnologies Appoints Elina Tea to its Board of DirectorsApril 3, 2024 | globenewswire.comTheratechnologies to Announce First Quarter 2024 Financial Results and Provide Business UpdateMarch 30, 2024 | stockhouse.comTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) PlatformMarch 28, 2024 | globenewswire.comTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ PlatformMarch 24, 2024 | investing.comTheratechnologies shifts focus, phases down preclinical researchMarch 22, 2024 | globenewswire.comTheratechnologies Announces Update on its Preclinical Oncology Research ProgramMarch 21, 2024 | globenewswire.comTheratechnologies Appoints Jordan Zwick to its Board of DirectorsMarch 21, 2024 | globenewswire.comTheratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 29, 2024 | globenewswire.comTheratechnologies Announces the Resignation of One of Its Directors, Mr. Alain TrudeauFebruary 27, 2024 | globenewswire.comTheratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDAFebruary 21, 2024 | washingtonpost.comTheratechnologies: Fiscal Q4 Earnings SnapshotFebruary 21, 2024 | globenewswire.comTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceFebruary 20, 2024 | globenewswire.comTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of ActionFebruary 15, 2024 | finance.yahoo.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerFebruary 15, 2024 | globenewswire.comTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerJanuary 24, 2024 | marketbeat.comTrading was temporarily halted for "THTX" at 06:01 AM with a stated reason of "News pending."January 23, 2024 | finance.yahoo.comTheratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License ApplicationJanuary 19, 2024 | msn.comUpcoming FDA Decision: How likely is approval for EGRIFTA MDV?January 6, 2024 | theglobeandmail.comWill This Dual-Listed Bio-Pharma Catch New Year Action?January 2, 2024 | finance.yahoo.comTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAJanuary 2, 2024 | finance.yahoo.comTheratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAJanuary 2, 2024 | markets.businessinsider.comTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDAJanuary 2, 2024 | markets.businessinsider.comTheratechnologies Files SBLA For Trogarzo Intramuscular Method Of Administration With FDADecember 21, 2023 | msn.comTheratechnologies files for $100M mixed securities shelfDecember 21, 2023 | msn.comTheratechnologies files for $100M mixed securities shelfDecember 21, 2023 | finance.yahoo.comTheratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration StatementDecember 13, 2023 | markets.businessinsider.comFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading DoseDecember 13, 2023 | markets.businessinsider.comFDA Approves Theratechnologies' Trogarzo 90-second IV Push Loading DoseDecember 13, 2023 | markets.businessinsider.comTheratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading DoseOctober 31, 2023 | finance.yahoo.comTheratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementOctober 26, 2023 | finance.yahoo.comTheratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementOctober 26, 2023 | investing.comTheratechnologies Revises Fiscal Revenue Target Amid Continuity ConcernsOctober 24, 2023 | finance.yahoo.comTheratechnologies Announces Operational UpdateOctober 19, 2023 | financialpost.comTheratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVOctober 19, 2023 | finance.yahoo.comTheratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVOctober 16, 2023 | stockhouse.comTheratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with MarathonOctober 16, 2023 | markets.businessinsider.comHold Rating on Theratechnologies Amid Mixed Trogarzo Performance and Future Growth PotentialOctober 13, 2023 | msn.comTheratechnologies says Trogarzo IM method of administration study did not meet primary endpointOctober 12, 2023 | finance.yahoo.comTheratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerOctober 4, 2023 | finance.yahoo.comTheratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLASeptember 25, 2023 | benzinga.comEarnings Outlook For Theratechnologies Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. THTX Media Mentions By Week THTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. THTX News Sentiment▼0.960.55▲Average Medical News Sentiment THTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. THTX Articles This Week▼21▲THTX Articles Average Week Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LPCN News Today DRRX News Today VIRX News Today IPA News Today DARE News Today APLM News Today APRE News Today ACXP News Today ENLV News Today NNVC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:THTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
